Essex Bio-Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Essex Bio-Technology şirketinin toplam hissedar öz sermayesi HK$2.0B ve toplam borcu HK$306.5M olup, bu da borç-öz sermaye oranını 15.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla HK$3.0B ve HK$950.3M dir. Essex Bio-Technology 'in FAVÖK'ü HK$321.4M faiz karşılama oranı -46.3 dur. Şirketin HK$600.6M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

15.2%

Borç/özkaynak oranı

HK$306.54m

Borç

Faiz karşılama oranı	-46.3x
Nakit	HK$600.62m
Eşitlik	HK$2.02b
Toplam yükümlülükler	HK$950.33m
Toplam varlıklar	HK$2.97b

Son finansal sağlık güncellemeleri

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Oct 09

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Mar 21

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Dec 07

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 07

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Aug 25

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Jun 22

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1061 'nin kısa vadeli varlıkları ( HK$1.4B ) kısa vadeli yükümlülüklerini ( HK$824.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1061 şirketinin kısa vadeli varlıkları ( HK$1.4B ) uzun vadeli yükümlülüklerini ( HK$126.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1061 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 1061 'nin borç/öz sermaye oranı son 5 yılda 22.1% seviyesinden 15.2% seviyesine düştü.

Borç Kapsamı: 1061 'nin borcu işletme nakit akışı ( 103% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 1061 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Essex Bio-Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 19%

First half dividend increased to HK$0.06

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

First half 2024 earnings released: EPS: HK$0.28 (vs HK$0.30 in 1H 2023)

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Investor sentiment improved over the past week

New 90-day high: HK$4.40

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

New 90-day low: HK$3.74

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?